UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

New Diagnostic Criteria for Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e4-e5

Rajkumar, S.V

2015

Volltextzugriff (PDF)

Debate - Change Therapy for High/Low Risk Patients - Yes

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e21-e21

Rajkumar, S.V

2015

Volltextzugriff (PDF)

Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Annals of oncology, 2017-02, Vol.28 (2), p.228-245

2017

Volltextzugriff (PDF)

Su1029 De Novo Celiac Autoimmunity and Natural History of Celiac Autoimmunity in Adults: A Population-Based Study

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S448-S448

2016

Volltextzugriff (PDF)

Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma

Leukemia, 2010-08, Vol.24 (8), p.1498-1505

2010

Volltextzugriff (PDF)

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Leukemia, 2009-01, Vol.23 (1), p.3-9

2009

Volltextzugriff (PDF)

THE HIGH COST OF CANCER DRUGS: WHAT CAN WE DO?

Hematological oncology, 2019-06, Vol.37 (S2), p.172-172

Rajkumar, S.V.

2019

Volltextzugriff (PDF)

N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression

Leukemia, 2020-10, Vol.34 (10), p.2749-2753

2020

Volltextzugriff (PDF)

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

Leukemia, 2013-04, Vol.27 (4), p.941-946

2013

Volltextzugriff (PDF)

S824 A PHASE 3 RANDOMIZED, OPEN‐LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW‐DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW‐DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

HemaSphere, 2019-06, Vol.3 (S1), p.365-n/a

2019

Volltextzugriff (PDF)

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

Leukemia, 2010-06, Vol.24 (6), p.1121-1127

2010

Volltextzugriff (PDF)

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

Leukemia, 2013-08, Vol.27 (8), p.1738-1744

2013

Volltextzugriff (PDF)

A simple model to predict survival using age, comorbidities and functional status in patients with multiple myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e94-e95

2015

Volltextzugriff (PDF)

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Leukemia, 2009-09, Vol.23 (9), p.1545-1556

2009

Volltextzugriff (PDF)

Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone (KRd) vs Lenalidomide and Dexamethasone (Rd) in Patients (Pts) With Relapsed Multiple Myeloma (RMM) Based on Age: Secondary Analysis From the Phase 3 Study ASPIRE (NCT01080391)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e75-e76

2015

Volltextzugriff (PDF)

Superior Health-Related Quality of Life with Carfilzomib, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma (MM): Results From the ASPIRE Trial

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e76-e76

2015

Volltextzugriff (PDF)

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Leukemia, 2009-02, Vol.23 (2), p.215-224

2009

Volltextzugriff (PDF)

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

Leukemia, 2013-03, Vol.27 (3), p.711-717

2013

Volltextzugriff (PDF)

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

Leukemia, 2013-03, Vol.27 (3), p.680-685

2013

Volltextzugriff (PDF)

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey

Leukemia, 2014-07, Vol.28 (7), p.1537-1542

2014

Volltextzugriff (PDF)

Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma

Leukemia, 2014-10, Vol.28 (10), p.2060-2065

2014

Volltextzugriff (PDF)

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

Leukemia, 2011-06, Vol.25 (6), p.906-908

2011

Volltextzugriff (PDF)

Treatment of newly diagnosed myeloma

Leukemia, 2009-03, Vol.23 (3), p.449-456

2009

Volltextzugriff (PDF)

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Leukemia, 2014-03, Vol.28 (3), p.525-542

2014

Volltextzugriff (PDF)

Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites

Leukemia, 2012-04, Vol.26 (4), p.609-614

2012

Volltextzugriff (PDF)

1 – 25 von 140

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(123)

Publikationsform

Sprache

Englisch
(139)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

New Diagnostic Criteria for Multiple Myeloma

Debate - Change Therapy for High/Low Risk Patients - Yes

Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Su1029 De Novo Celiac Autoimmunity and Natural History of Celiac Autoimmunity in Adults: A Population-Based Study

Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

THE HIGH COST OF CANCER DRUGS: WHAT CAN WE DO?

N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

S824 A PHASE 3 RANDOMIZED, OPEN‐LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW‐DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW‐DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

A simple model to predict survival using age, comorbidities and functional status in patients with multiple myeloma (MM)

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone (KRd) vs Lenalidomide and Dexamethasone (Rd) in Patients (Pts) With Relapsed Multiple Myeloma (RMM) Based on Age: Secondary Analysis From the Phase 3 Study ASPIRE (NCT01080391)

Superior Health-Related Quality of Life with Carfilzomib, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma (MM): Results From the ASPIRE Trial

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey

Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

Treatment of newly diagnosed myeloma

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites

Suchergebnisse filtern